IBRX
ImmunityBio, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 20 to Feb 24 ▼ 3 days of insider sells: $2.9M by 2 insiders, avg $10.67
- Feb 28 ▲ Three major passive institutional investors, Morgan Stanley, Wells F…
- Apr 9 ▲ ImmunityBio reported preliminary Q1 2026 net product revenue of $44.…
- Jun 4 ▼ 1 insider sell $165.3K at $7.18
- Jun 24 to Jul 2 ▼ 5 days of insider sells: $3.8M by 3 insiders, avg $9.10
- Sep 28 to Sep 30 ▲ 2 buys: Lisa McClain bought $1,001 - $15,000, last disclosed Oct 13
- Oct 2 to Oct 5 ▼ 2 days of insider sells: $1.1M by 2 insiders, avg $10.56
- Oct 14 ▲ ImmunityBio announced FDA approval expanding ANKTIVA's indication to…
- Nov 9 ▲ ImmunityBio announced positive final analysis results from the QUILT…
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $8.0M.
- InstitutionsMIXED
Q3 2026: 31 added (0 new), 21 trimmed or exited.
- AnalystsBULLISH
9 of 10 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +2.5% to 126.08M shares. 10.8 days to cover, ≈11.9% of shares.
- TrendDOWNTREND
30% below its 50-day average.
- SocialQUIET
Crowd 60° (warm) this week from 1 mention: 1 bullish, 0 bearish. No setup is alerting.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | TRIM | $20.1M |
| PRINCIPAL FINANCIAL GROUP INC | DOUBLED | $16.4M |
| MARSHALL WACE, LLP | DOUBLED | $13.7M |
| Private Advisor Group, LLC | DOUBLED | $8.4M |
| Invesco Ltd. | ADD | $5.3M |
| Rafferty Asset Management, LLC | ADD | $4.8M |
| VANGUARD ASSET MANAGEMENT, Ltd | ADD | $3.5M |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | $2.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
10 analystsPrice is below the lowest target. Median implies +142%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 15, 2026 | Jefferies MAINTAIN | Buy |
| Oct 15, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Jun 2, 2026 | HC Wainwright & Co. REITERATE | Buy |
| May 21, 2026 | BTIG REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Simon Barry J. Director Oct 5, 2026 | SELL | $268.8K |
Cohen Cheryl Director Oct 2, 2026 | EXERCISE | $166.8K |
Cohen Cheryl Director Oct 2, 2026 | SELL | $851.1K |
Cohen Cheryl Director Jul 2, 2026 | EXERCISE | $166.8K |
Cohen Cheryl Director Jul 2, 2026 | SELL | $1.2M |
Selecky Christobel Director Jul 1, 2026 | EXERCISE | $372.0K |
Selecky Christobel Director Jul 1, 2026 | SELL | $1.4M |
Selecky Christobel Director Jul 1, 2026 | EXERCISE | $104.5K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
11 filings · 5 bullish · 0 bearish · 6 neutral- NEUTRAL 8-KNov 9, 2026
ImmunityBio reported Q3 2026 net product revenue of $48.7M, up 53% YoY, but missed consensus…
Revenue miss vs consensus is notable but the FDA label expansion and positive BCG-naive trial data support a larger addressable market. Monitor Q4 revenue trajectory and the upcoming sBLA submission…
- BULLISH 8-KNov 9, 2026
ImmunityBio announced positive final analysis results from the QUILT-2.005 trial, showing ANKTIVA…
Monitor the sBLA submission by year-end 2026 and FDA acceptance/priority review decision. Full study details at an upcoming medical congress may provide additional efficacy and durability data. The…
- NEUTRAL INST-CLUSTERNov 4, 2026
Three institutional asset managers added $18.3M in IBRX positions during Q3 2026, led by Principal…
The cluster is small relative to IBRX's $8.8B market cap and consists of asset managers rather than activist or event-driven funds. The 45-day reporting lag means these Q3 positions may have already…
- BULLISH 8-KOct 14, 2026
ImmunityBio announced FDA approval expanding ANKTIVA's indication to include BCG-unresponsive…
Monitor upcoming quarterly earnings for initial commercial uptake metrics in the newly approved papillary-only segment. The expanded label creates a first-mover advantage in a large underserved…
All IBRX filing & press-release reports (11)
- 8-K reportNov 9, 2026
- 8-K reportNov 9, 2026
- INST-CLUSTER reportNov 4, 2026
- 8-K reportOct 14, 2026
- 8-K reportAug 4, 2026
- CLUSTER reportJul 6, 2026
- CLUSTER reportJul 1, 2026
- 8-K reportMay 18, 2026
- 8-K reportApr 9, 2026
- 8-K reportApr 6, 2026
- INST-CLUSTER reportFeb 28, 2026